Literature DB >> 11916076

The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C).

Midori Shima1, Tomoko Matsumoto, Kazuyoshi Fukuda, Youko Kubota, Ichiro Tanaka, Katumi Nishiya, Alan R Giles, Akira Yoshioka.   

Abstract

The lower detection limit of the conventional one-stage aPTT based clotting assay for determining FVIII:C levels is generally 1.0-2.0 IU/dl. Consequently, it has been impossible to study the clinical significance of levels of FVIII:C less than 1.0 IU/dl. Using a photo-optical automated coagulation analyzer, the Organon Teknika MDA II, we have performed qualitative and quantitative aPTT waveform analysis and measured FVIII:C levels by automated one-stage aPTT clotting assay in 36 severely affected Hemophilia A patients. Qualitative waveform analysis showed clear evidence of individual differences in the waveform profile suggesting differing coagulant activity from patient to patient. The FVIII:C level was less than 0.2 IU/dl in 23 cases and levels of FVIII:C between 0.2 and 1.0 IU/dl could be discriminated in 13 patients. The FVIII:C level in these patients was closely correlated with the minimum value of the second derivative of the aPTT waveform (Min2). This is a measure of the acceleration of change in optical transmission at the initiation of coagulation. Furthermore, the correlation of the

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11916076

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  9 in total

1.  A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity.

Authors:  Tomoko Matsumoto; Keiji Nogami; Midori Shima
Journal:  Int J Hematol       Date:  2016-10-11       Impact factor: 2.490

2.  A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A.

Authors:  Tomoko Matsumoto; Keiji Nogami; Kenichi Ogiwara; Midori Shima
Journal:  Int J Hematol       Date:  2009-11-25       Impact factor: 2.490

3.  Inversions of the factor VIII gene in Japanese patients with severe hemophilia A.

Authors:  Kazuyoshi Fukuda; Hiroyuki Naka; Shogo Morichika; Masaru Shibata; Ichiro Tanaka; Midori Shima; Akira Yoshioka
Journal:  Int J Hematol       Date:  2004-04       Impact factor: 2.490

4.  Diagnostic analysis of lupus anticoagulant using clot waveform analysis in activated partial thromboplastin time prolonged cases: A retrospective analysis.

Authors:  Kazunori Kanouchi; Hiroto Narimatsu; Toru Shirata; Keita Morikane
Journal:  Health Sci Rep       Date:  2021-03-12

Review 5.  Advances in laboratory assessment of thrombosis and hemostasis.

Authors:  Jaewoo Song
Journal:  Blood Res       Date:  2022-04-30

6.  Usefulness of the second-derivative curve of activated partial thromboplastin time on the ACL-TOP coagulation analyzer for detecting factor deficiencies.

Authors:  Naoki Tokunaga; Chihiro Inoue; Toshiyuki Sakata; Kumiko Kagawa; Masahiro Abe; Norimichi Takamatsu; Takayuki Nakao; Toshio Doi
Journal:  Blood Coagul Fibrinolysis       Date:  2016-06       Impact factor: 1.276

7.  Global coagulation assays in hemophilia A: A comparison to conventional assays.

Authors:  Saman Aghighi; Anne Riddell; Christine A Lee; Simon A Brown; Edward Tuddenham; Pratima Chowdary
Journal:  Res Pract Thromb Haemost       Date:  2019-12-29

8.  Update on the Clot Waveform Analysis.

Authors:  Hideo Wada; Takeshi Matsumoto; Kohshi Ohishi; Katsuya Shiraki; Motomu Shimaoka
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

9.  Clot Waveform Analysis Demonstrates Low Blood Coagulation Ability in Patients with Idiopathic Thrombocytopenic Purpura.

Authors:  Hideo Wada; Yuhuko Ichikawa; Minoru Ezaki; Katsuya Shiraki; Isao Moritani; Yoshiki Yamashita; Takeshi Matsumoto; Masahiro Masuya; Isao Tawara; Hideto Shimpo; Motomu Shimaoka
Journal:  J Clin Med       Date:  2021-12-20       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.